Vaniprevir - Misplaced Pages

Chemical compound

Pharmaceutical compound

Vaniprevir
Identifiers

IUPAC name (1R,21S,24S)-21-tert-butyl-N--16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracycloheptacosa-6(11),7,9-triene-24-carboxamide
CAS Number	923590-37-8
PubChem CID	24765256
DrugBank	DB11929
ChemSpider	24651717
UNII	CV3X74AO1H
ChEBI	CHEBI:136047
ChEMBL	ChEMBL4525964
CompTox Dashboard (EPA)	DTXSID201029738
ECHA InfoCard	100.207.830
Chemical and physical data
Formula	C₃₈H₅₅N₅O₉S
Molar mass	757.94 g·mol
3D model (JSmol)	Interactive image
SMILES CC1C1(C(=O)NS(=O)(=O)C2CC2)NC(=O)3C4CN3C(=O)(NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C
InChI InChI=InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1 Key:KUQWGLQLLVFLSM-ONAXAZCASA-N

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.

References

McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, et al. (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176.
"First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
"New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency. Archived from the original (PDF) on 2015-05-13. Retrieved 2015-08-22.

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Ciluprevir Danoprevir Faldaprevir Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir Telaprevir Vaniprevir Vedroprevir Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir Elbasvir Ledipasvir Odalasvir Ombitasvir Pibrentasvir Ravidasvir Ruzasvir Samatasvir Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir Bemnifosbuvir Dasabuvir Deleobuvir Filibuvir GS-6620 IDX-184 Setrobuvir Sofosbuvir Tegobuvir TMC-647055 Radalbuvir Uprifosbuvir
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir/voxilaprevir

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a Peginterferon alfa-2b
3CL protease inhibitors (–trelvir)	Ensitrelvir Ibuzatrelvir Lufotrelvir Nirmatrelvir (+ritonavir) Rupintrivir Simnotrelvir (+ritonavir)
RNA pol inhibitors	CMX521 Deuremidevir Favipiravir Galidesivir GS-441524 Remdesivir MK-608 Mericitabine Molnupiravir NITD008 Ribavirin Taribavirin Triazavirin Valopicitabine
Multiple/Unknown/Other	EICAR Merimepodib Moroxydine Presatovir

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.